Abstract
Introduction
Coronary bypass surgery in patients operated on within 48 hr of Q-wave myocardial infarction is associated with a higher operative mortality than surgery in such patients operated upon after this time [1] . Similarly, coronary bypass within 1 week of myocardial infarction is associated with more post-operative complications than is surgery in postinfarction patients operated upon later in their recovery [2] .
An important contributing factor to these unfavourable results may be the adverse response to cardioplegic arrest of the surviving, but stressed, non-infarcted areas of myocardium. In the first few days after major acute m cardial infarction, the non-infarcted myocardium, rem from the infarct, manifests depressed contractility [3] a biochemical perturbations including decreased levels glycogen [4] and high energy phosphates [5, 6] . Thus, the presence of recent infarction the surviving myocardiu when subjected to a period of cardioplegic arrest w impaired contractile function and depleted energy stor is highly vulnerable to ischemic injury.
We, and others, have shown that metabolic supplemen tion with aspartate in the cardioplegic solution improves tolerance of normal hearts to global ischemia at normoth mia or hypothermia, and that aspartate is more effect than glutamate in this regard [7, 8] although other investi tors have not shown this effect in neonatal myocardium or under hypothermic conditions [10] . Likely mechanis European Journal of Cardio-thoracic Surgery 14 (1998) [185] [186] [187] [188] [189] [190] of action are prevention of ischemia-induced depletion of tricarboxylic acid cycle intermediates and stimulation of the malate-aspartate shuttle. Whether supplementation of cardioplegia with aspartate would be effective in the recently infarcted heart has not been previously investigated. We therefore set out to study, in the rat, the effect of aspartate added to the cardioplegic solution in the setting of recent myocardial infarction.
Methods

Production of myocardial infarction
Anaesthesia was induced in male Munich Wistar rats, weighing 280-380 g, by intra-peritoneal injection of pentobarbitone (15 mg/kg), methohexitone (60 mg/kg) and atropine (0.5 mg/kg). After endotracheal intubation, mechanical ventilation was commenced. A thoracotomy was performed through the left 4th intercostal space and the left coronary artery was ligated. Coronary occlusion was verified by discolouration of the distal myocardium. The thoracotomy was closed and the animal allowed to recover. In pilot studies in 15 rats this procedure produced an infarct of predictable size, 35.5 ± 1.81% of the left ventricle, measured by weighing after nitroblue tetrazolium delineation of the infarct [11] . All animals were treated in accordance with the Code of Practice for Animal Experimentation of the National Health and Medical Research Council of Australia.
Isolated working heart preparation
Twenty hours after coronary occlusion, under halothane anaesthesia, the heart was rapidly excised and immersed in Krebs Henseleit solution at 4°C. On an isolated working rat heart apparatus [12] the aorta was cannulated and retrograde perfusion commenced for a 15 min stabilisation period with oxygenated (PO 2 500 mmHg) Krebs Henseleit bicarbonate buffer at 37°C. During this period, left atrial cannulation was carried out to convert the heart to the working mode. Hearts were then randomly assigned to either the aspartate cardioplegia or the non-aspartate cardioplegia (untreated) group.
Experimental time sequence
To simulate the events of an open heart operation, the following experimental time sequence of five time periods was employed. At the end of each working period, cardiac function was measured under the standard loading conditions (LAP, 15 cm H 2 O; aortic column, 100 cm H 2 O). The power output (rate of performing external work) of the heart was calculated using the formula:
where W P is the power (rate of performing work) in mJ/s, P dev is the developed pressure in mmHg (systolic aortic pressure minus left atrial pressure) and CO is the cardiac output in ml/min (aortic flow plus coronary flow). A conversion factor for SI units (0.0022) is included. Five hearts were excluded because they showed very low initial power (less than 2.7 mJ/s).
To determine oxygen consumption, oxygen tension was measured in samples collected from the inflow line (arterial sample) and from the pulmonary artery (venous sample). Oxygen consumption per gram was calculated using the formula [13] :
where MVO 2 is oxygen consumption in ml/min per g, P a O 2 and P v O 2 are partial pressures of oxygen in mmHg in the arterial and venous samples respectively, 760 is the barometric pressure in mmHg, CF is coronary flow in ml/min, and W is wet heart weight in grams. Myocardial efficiency was calculated by dividing power (mJ/s per g), by MVO 2 (ml/min per g) and expressing the result as a percentage of the expected energy equivalent of complete oxygen combustion, which is 20.97 J/ml of O 2 [14] :
Cardioplegic solutions
For the untreated group the cardioplegic solution was modified Ringer's solution containing 20 mM KCl, 127 mM NaCl and 2 mM CaCl 2 at pH 7.4, oxygenated with a mixture of 95% O 2 and 5% CO 2 . In the aspartate group, 20 mM sodium aspartate was added to the solution and the amount of NaCl was decreased to keep the sodium concentration and osmolarity unchanged.
Tissue sampling and biochemical analysis
The non-infarcted region of each heart (including the right ventricle) was rapidly freeze-clamped with tongs precooled in liquid nitrogen either at the end of cardioplegic arrest or at the end of reperfusion. Tissue samples were stored in liquid nitrogen. Before assay the frozen tissue was pulverized in a mortar with liquid nitrogen and extracted with ice-cold perchloric acid. Tissue extracts were neutralised and used for spectrophotometric enzymatic assays of ATP, ADP, AMP, phosphocreatine (PCr) and aspartate using standard enzymatic techniques [15] on a Cobas Bio autoanalyser (Roche Diagnostic Systems).
Statistics
All results are expressed as the mean ± SEM. For biochemical data unpaired t-tests were used to compare aspartate-treated with untreated values. Since the physiological measurement values were not normally distributed, nonparametric tests were used: the Wilcoxon signed rank test for pre-versus post-arrest values, and the Mann-Whitney rank sum test for aspartate-treated versus untreated. P Ͻ 0.05 was considered statistically significant.
Results
Physiological measurements
There were no significant differences in any of the pre-arrest measurements between the untreated and aspartate-treated groups (Table 1 ). In the untreated group cardioplegic arrest produced highly significant decreases in aortic flow, systolic aortic pressure, power, oxygen consumption and efficiency. In the aspartate-treated group, cardioplegic arrest produced similar decreases in power, aortic flow and efficiency but not in aortic pressure or oxygen consumption. After reperfusion, the aspartate group generated more power (3.4 ± 0.2 mJ/s per g) than the untreated group (2.5 ± 0.3 mJ/s per g) (P Ͻ 0.05) such that the percentage recovery of pre-arrest power was greater in the aspartate group (67.7 ± 3.5%) than in the untreated group (53.6 ± 4.9%) (P Ͻ 0.05) (Fig. 1 ). There were similar improvements in the aspartate group in absolute values aortic flow and myocardial oxygen consumption compa to the untreated group (P Ͻ 0.05). Percentage recovery aortic flow after arrest also tended to be greater in the asp tate group than in the untreated group (P = 0.053) (Table There was no difference between the two groups in co nary blood flow or efficiency either before or after arr (Table 1) .
Biochemical measurements
At the end of cardioplegic arrest myocardial total a nine nucleotide levels ( Table 2) were low in both grou compared to values obtained from normal rat hea placed on the same apparatus and subjected to the sa period of normothermic global ischemia under identi conditions in our laboratory [7] . Ischemia caused bre down of ATP to ADP and AMP with a reduction in ene charge. After reperfusion ATP levels returned tow normal in both groups by reconstitution from ADP a AMP. Phosphocreatine was low at the end of ischem with a return to normal after reperfusion. There were between-treatment differences in high energy ph phates either at the end of ischemia or after reperfusi At the end of cardioplegic arrest there was a higher m cardial level of aspartate in the aspartate-treated gro 54.7 ± 9.6 mmol/g dry wt. than in the untreated gro 10.4 ± 5.6 mmol/g dry wt. (P Ͻ 0.01), a difference seen after reperfusion.
Discussion
This study shows that recovery of infarcted rat hearts improved after cardioplegic arrest by the addition of asp tate to the cardioplegic solution. This improvement is o similar magnitude to our previous observations in normal hearts [7] . Despite the improved function, aspartate supp mentation was not associated with increases in static lev of myocardial high energy phosphates either at the end arrest or after reperfusion. Table 1 Physiological measurements before and after arrest (n = 11 per group) 139.3 ± 7.6 145.6 ± 6.6 117.3 ± 6.8** 145.6 ± 9.6 † 84.9 ± 3.9 100.0 ± 4.1 † Efficiency (%)
9.3 ± 0.5 9.9 ± 0.3 5.8 ± 0.5* 6.8 ± 0.5** 63.5 ± 5.6 67.1 ± 3.0 Heart rate (bpm) 247 ± 8.0 267 ± 8.0 229 ± 9.0 256 ± 7.0 93.3 ± 4.2 96.6 ± 3.1
Post-arrest versus pre-arrest: *P Ͻ 0.01, **P Ͻ 0.001. Aspartate treated versus untreated: †P Ͻ 0.05. 
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Importance of metabolic correction for infarcted hearts prior to cardioplegia
We, and others, have shown that there are many metabolic disturbances in the non-infarcted zone of the recently infarcted heart, in particular, depletion of high energy phosphates [4] [5] [6] . We have previously shown in the rat and the dog that, compared with normal hearts, these energydepleted, recently infarcted hearts show reduced recovery from cardioplegic arrest [4, 6, 16, 17] . We have shown that infarcted hearts enter cardioplegic arrest with depleted energy stores in the surviving myocardium, and that this may compromise recovery from arrest. Thus, patients with post-infarction cardiogenic shock or failed angioplasty, who require cardiac surgery, may benefit from metabolic support to minimise metabolic disturbances in the myocardium and improve post-operative recovery.
The original metabolic supplement for infarcted hearts was glucose-insulin-potassium (GIK). However, conflicting data on the use of GIK for acute myocardial infarction have discouraged its widespread use as metabolic support for this and other cardiac problems [18] . The efficacy of warm induction and warm reperfusion ('hot shot') with blood cardioplegia, supplemented with the amino acid glutamate, in patients with post-infarction cardiogenic shock undergoing coronary bypass has been shown in a non-randomised patient series [19] . However, how much of the favourable effect in this high risk group of patients was attributable to the 'hot shot' itself and how much to the effect of glutamate supplementation was not clear.
Another approach to metabolic supplementation for infarcted hearts is the use of the pyrimidine precursor, orotic acid. In experimental studies [4, 16, 17] in recently infarcted rat or dog hearts undergoing cardioplegic arrest, orotic acid therapy produced a powerful cardioprotective effect. Treatment with orotate after recent infarction and before urgent surgery, followed by aspartate supplementation of the cardioplegic solution is a logical combination of two forms of metabolic supplementation, and is a therapy that we use in patients with recent infarction undergoing coronary bypass surgery at the Alfred Hospital.
Mechanisms of aspartate action
There are anaplerotic, anaerobic, and aerobic mechanisms of aspartate action [7] all of which can be shown to operate under certain conditions [20] .
The anaplerotic action of aspartate postulated by Russell and Taegtmeyer [21] means that the deficiencies of the tricarboxylic acid (TCA) cycle intermediates known to occur after ischemia can be immediately met within the mitochondria by replenishment of TCA cycle intermediates [22] via transamination of exogenous aspartate to oxaloacetate and conversion to malate [21] . Thus, during ischemia in aspartate-treated hearts the TCA cycle intermediates are well maintained, so that the TCA cycle is prepared to function more efficiently during reperfusion, i.e. 'priming the pump'. This mechanism is tightly linked with stimulation of the energy-producing reactions in mitochondria coupled to succinate formation and thus with enhancement of anaerobic ATP production [23] .
During reperfusion, aspartate may act aerobically by stimulating the operation of the malate-aspartate shuttle and TCA cycle [24] . At the end of cardioplegic arrest, in the present study, the aspartate level was 5-fold higher in the treated group. Presumably this increment reflects a rise of aspartate level both in the extracellular space and in the intracellular fluid. Thus, aspartate would have been able to affect aerobic intracellular metabolism in the critical early phase of reperfusion. Aspartate carries reducing equivalents obtained from cytosolic NADH (generated by glycolysis) into the mitochondria where they donate electrons to the electron transport system to form ATP. This action operates only under aerobic conditions.
The postulated anaerobic action of aspartate is to enhance ATP production during ischemia by stimulating nicotinamide adenine dinucleotide reoxidation which prevents the ischemia-induced arrest of glycolysis at the glyceraraldehyde phosphate dehydrogenase step. Oxaloacetate is formed by transamination of aspartate in the cytoplasm and the resulting amino acid group is transferred to pyruvate to form alanine via an intermediate reaction involving glutamate [22] . However, we found no increase in myocardial ATP at the end of ischemia in the aspartate-treated group. This is in accord with other observations in our laboratory using NMR spectroscopy showing that, although aspartate improved recovery after ischemia, there was no aspartate-induced increase in ATP during ischemia [25] . Thus, an anaerobic action of aspartate is unlikely in the present study.
Critique of the study
The concentration of aspartate of 20 mM was chosen on the basis of two previous studies of normal rat hearts, one from our laboratory [7] and another from that of Choong [8] showing a marked protective effect of aspartate in the cardioplegic solution at this concentration. In this study we have shown the beneficial effect of aspartate supplementation for cardioplegia in recently infarcted hearts. To bring out differences in recovery between aspartate-supplemented and non-supplemented groups we employed incomplete protection by using a simple cardioplegic solution containing potassium alone and without hypothermia. We did not include a non-infarcted group in the present study. However, in our previous study of normal rat hearts [7] the beneficial effect of aspartate-supplemented cardioplegia (50% recovery of function versus 32% in the control group) was of a similar magnitude to that found in the present study.
The procedure of coronary ligation in our hands produces an infarct of very predictable size [6, 16, 17 ]. In the current study a pilot group of coronary ligations produced infarcts of 35.5 ± 1.8% of ventricular weight. In the two groups of the main study, infarct size could not be measured cause the majority of the non-infarcted myocardium w removed by freeze clamping for biochemical analy However, there was no significant difference in funct between the aspartate group and the untreated cont group (both reduced to 30% of that in non-infarcted hearts in our previous study (16 mJ/s per g) [7] ), indicat that infarct sizes were also not different between the t groups.
Such a large infarct places a severe stress on the n infarcted area (60%) of the left ventricle which is thus cal upon to maintain the entire cardiac output. This, in tu would place stress on metabolic pathways for energy p duction, pathways which would be likely to benefit fr appropriate metabolic supplementation.
Theoretically, aspartate involvement in energy meta lism should result in measurable elevations in myocard high energy phosphates. However, in the present stu despite their improved functional recovery, aspartate-tr ted hearts did not exhibit enhanced cellular energy state evidenced by raised tissue content of adenine nucleotid phosphocreatine and increased energy charge either at end of arrest or after reperfusion (Table 2 ). This can explained in part by the relatively small ATP deplet after arrest and reperfusion, to 73% of normal in the cont group, which may not have been sufficiently severe to br out the effect of aspartate on myocardial levels of h energy phosphates. Additionally, a small increment ATP produced by aspartate might be rapidly utilised more effective myofibril contraction and thus not be dete able in static tissue levels of ATP. Furthermore it is kno that myocardial metabolite contents do not necessar reflect the rate of turnover of metabolic cycles which m be both effectively triggered and coupled by aspartate tra amination. Table 2 Effects of global ischemia and reperfusion, and aspartate cardioplegia on high energy phosphates
End of arrest Reperfusion
Untreated n = 7 Aspartate treated a n = 7 Untreated n = 7 Aspartate treated a n = 8 ATP (mmol/g dry wt.) (20. Normal values given in parentheses are from our previous study of six isolated perfused non-infarcted rat hearts without cardioplegic arrest [7] . a There were no significant differences between treatment groups either at the end of ischemia or after reperfusion. b Energy charge, (ATP + 1/2 ADP)/TAN. ATP, adenosine tri-phosphate; ADP, adenosine di-phosphate; AMP, adenosine mono-phosphate. 
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Conclusion
We have shown that aspartate protects the recently infarcted heart during cardioplegic arrest and is at least as beneficial in recently infarcted hearts as in normal hearts. Although the mechanism of action of aspartate in the ischemic myocardium was not addressed in this study, we did find that aspartate improved functional recovery by augmenting myocardial energy production mainly during early post-ischemic reperfusion. Given the fact that patients with recent infarction are a high risk group for cardiac surgery, we recommend, and routinely use metabolic therapy with aspartate in our clinical practice in these patients.
